Vonvendi Launches in the U.S. Market

Shire has launched the first recombinant treatment for von Willebrand factor in the U.S.

The drug was approved in December after a pivotal study demonstrated that all participants reported successful treatment of bleeding episodes.

The company did not detail its release plans or price point for the drug. — Cynthia Jessup